Breaking news in hematology-oncology

The American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, was held on the 1–4 December.

Explore the news from big trials, updates from key pivotal studies, exciting discoveries in disease biology, as well as the latest CAR T-cell data and MRD insights, and late-breaking abstracts.

View all videos

ASH 2018

American Society of Hematology (ASH) Annual Meeting and Exposition

San Diego, 1–4 December 2018

ASH 2018

American Society of Hematology (ASH) Annual Meeting and Exposition

San Diego, 1–4 December 2018

Breaking news in hematology-oncology

The American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, was held on the 1–4 December.

Explore the news from big trials, updates from key pivotal studies, exciting discoveries in disease biology, as well as the latest CAR T-cell data and MRD insights, and late-breaking abstracts.

View all videos

CLL

View all

Venetoclax and bendamustine plus rituximab or obinutuzumab for CLL

Stephan Stilgenbauer

Ibrutinib emerging as the new standard of care for frontline elderly CLL: ALLIANCE results

Jennifer Woyach

MM

View all

Quadruplet regimens for newly diagnosed myeloma & MRD-tracking of DKRd-treated patients

Ixazomib prolongs PFS following ASCT in newly diagnosed myeloma

Vincent Rajkumar

Breaking Data

Watch the press briefs and late-breaking abstracts.

Big trials with big results, new and novel agents, CAR T-cell therapies, non-malignant pathologies, and pivotal study updates.

Waldenström’s

View all

Association between depth of response and survival in Waldenström’s

Mass spectrometry-flow cytometry study of IgM MGUS progression to Waldenström’s

AML

View all

An update on AMG-330: can BiTEs be as successful in AML as ALL?

Marion Subklewe

E-selectin antagonist uproleselan for R/R AML: efficacy and safety data

Daniel DeAngelo

CAR T-cells

The latest CAR T-cell data is here, and we’re seeing lots of new exciting agents on the horizon.

Find out all the news from recently approved treatments, as well as the most promising new CARs in the hematology arena, here.

Lymphoma

View all

Updated JULIET results for tisagenlecleucel in DLBCL

Richard Thomas Maziarz

R2 in the second-line: lenalidomide-rituximab improves PFS in relapsed/refractory NHL

ALL

View all

Initial data for CAR T-cell product JCAR021 in ALL and B-cell lymphoma

Jordan Gauthier

Updated pivotal ELIANA study results for CAR T-cell product tisagenlecleucel in ALL

Measurable Residual Disease

The assessment of MRD status has gone from strength to strength.

At ASH we spoke to world-leading experts about the latest on MRD-guided treatment, NGS vs. MFC for measurement, and more.

Sickle Cell Disease & β-Thalassemia

View all

BELIEVE: β-thalassemia treatment with luspatercept reduces transfusion burden

Maria D. Cappellini et al.

Opioid use in sickle cell is not associated with in-hospital mortality in the US

Oladimeji Akinola Akinboro

Trial Updates

View all

Updates from MURANO for CLL: time-limited VenR & impact of MRD

Reduced R-CHOP in favourable-prognosis DLBCL doesn’t compromise outlook

Mohamad and Saad’s ASH Takeaway

Your definitive guide to multiple myeloma at ASH 2018.

Covering the latest trial data, transplant updates, MRD, CAR-T and BiTEs, promising novel agents, and beyond.